Vertex Pharmaceuticals Incorporated
US ˙ NasdaqGS ˙ US92532F1003

SecurityVRTX / Vertex Pharmaceuticals Incorporated
InstitutionAmalgamated Bank
Latest Disclosed Ownership53,269 shares
Latest Disclosed Value $ 23,787
Amalgamated Bank reports 3.36% decrease in ownership of VRTX / Vertex Pharmaceuticals Incorporated

On May 8, 2026 - Amalgamated Bank filed a 13F-HR form disclosing ownership of 53,269 shares of Vertex Pharmaceuticals Incorporated (US:VRTX) valued at $23,786,739 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 5, 2026 disclosing 55,120 shares of Vertex Pharmaceuticals Incorporated. This represents a change in shares of -3.36% during the quarter. The current value of the position is $22,817,243 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-05-08 2026-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 53,269 -1,851 -3.36 24 -4.17 0.1820
2026-02-05 2025-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 55,120 -1,394 -2.47 25 9.09 0.1804
2025-10-29 2025-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 56,514 779 1.40 22 -8.33 0.1581
2025-08-04 2025-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 55,735 2,005 3.73 25 -7.69 0.1915
2025-04-25 2025-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 53,730 726 1.37 26 23.81 0.2229
2025-02-04 2024-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 53,004 -3,186 -5.67 21 -19.23 0.1752
2024-10-30 2024-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 56,190 2,383 4.43 26 4.00 0.2153
2024-08-12 2024-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 53,807 -1,801 -3.24 25 8.70 0.2148
2024-04-23 2024-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 55,608 -8,932 -13.84 23 -11.54 0.1988
2024-02-06 2023-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 64,540 -3,649 -5.35 26 13.04 0.2095
2023-11-08 2023-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 68,189 -8,261 -10.81 24 -11.54 0.2019
2023-08-11 2023-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 76,450 -4,647 -5.73 27 4.00 0.2177
2023-05-02 2023-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 81,097 11,188 16.00 26 25.00 0.2178
2023-02-10 2022-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 69,909 -5,767 -7.62 20 -99.91 0.1800
2022-11-09 2022-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 75,676 6,579 9.52 21,911 12.53 0.2115
2022-08-15 2022-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 69,097 -292 -0.42 19,471 7.53 0.1815
2022-08-25 2022-03-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 69,389 -1,785 -2.51 18,108 15.85 0.1407
2022-06-30 2022-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 69,389 -1,785 18,108 0.1438
2022-02-15 2021-12-31 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 71,174 5,885 9.01 15,630 31.98 0.1154
2022-02-15 2021-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 71,174 5,885 15,630 0.1154
2021-10-29 2021-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 65,289 -2,652 -3.90 11,843 -13.55 0.1000
2021-08-16 2021-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 67,941 51,971 325.43 13,699 299.16 0.1098
2021-05-13 2021-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 15,970 -762 -4.55 3,432 -13.20 0.1287
2021-02-12 2020-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 16,732 -93 -0.55 3,954 -13.63 0.1498
2020-10-30 2020-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 16,825 -497 -2.87 4,578 -8.97 0.1990
2020-08-10 2020-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 17,322 -26,032 -60.05 5,029 -51.25 0.2327
2020-05-13 2020-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 43,354 -1,051 -2.37 10,316 6.11 0.2522
2020-02-13 2019-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 44,405 1,776 4.17 9,722 34.62 0.1789
2019-11-13 2019-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 42,629 8,614 25.32 7,222 15.77 0.1519
2019-08-14 2019-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 34,015 -4,339 -11.31 6,238 -11.58 0.1456
2019-05-15 2019-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 38,354 815 2.17 7,055 13.41 0.1710
2019-02-15 2018-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 37,539 -1,024 -2.66 6,221 -16.31 0.1763
2018-11-14 2018-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 38,563 -1,209 -3.04 7,433 9.96 0.1838
2018-07-18 2018-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 39,772 2,880 7.81 6,760 12.42 0.1652
2018-05-22 2018-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 36,892 3,623 10.89 6,013 20.60 0.1595
2018-02-13 2017-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 33,269 2,921 9.63 4,986 8.06 0.1349
2017-11-09 2017-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 30,348 1,082 3.70 4,614 22.32 0.1437
2017-08-10 2017-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 29,266 10,589 56.70 3,772 84.72 0.1236
2017-05-12 2017-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 18,677 -8,020 -30.04 2,042 3.81 0.1016
2017-02-14 2016-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 26,697 4,651 21.10 1,967 2.29 0.0889
2016-11-15 2016-09-30 13F/A-1 VERTEX PHARMACEUTICALS COM 92532F100 22,046 54 0.25 1,923 -13.61 0.1116
2016-11-14 2016-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,426 560
2016-08-16 2016-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 21,992 12,289 126.65 2,226 188.72 0.1288
2016-05-11 2016-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 9,703 2,313 31.30 771 -17.10 0.0751
2016-02-10 2015-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 7,390 -1,870 -20.19 930 -3.53 0.1147
2015-11-04 2015-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 9,260 345 3.87 964 -12.44 0.1011
2015-07-10 2015-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 8,915 630 7.60 1,101 12.69 0.1081
2015-04-22 2015-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 8,285 8,285 0.00 977 0.1193
2015-01-29 2014-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -7,275 -100.00 0 -100.00
2014-11-14 2014-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 7,275 459 6.73 817 26.67 0.1216
2014-08-11 2014-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 6,816 865 14.54 645 53.21 0.0973
2014-05-12 2014-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,951 -113 -1.86 421 -6.65 0.0725
2014-02-13 2013-12-31 13F VERTEX PHARMACEUTICALS COM 92532F100 6,064 6,064 12.90 451 52.88 0.0767
2013-11-14 2013-09-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 0 0 0.0000
2013-08-15 2013-06-30 13F VERTEX PHARMACEUTICALS COM 92532F100 0 -5,371 -100.00 0 -100.00
2014-02-13 2013-03-31 13F VERTEX PHARMACEUTICALS COM 92532F100 5,371 5,371 295 0.0837
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.